Renal cancer and treatment of prostate cancer
Poster Session 3
Friday 25 May
16:30 - 17:45

Location: Beta Room 1
Chairs: M. Jievaltas, Kauno Rajonas (LT)
T. Murtola, Kangasala (FI)

34

By: Sepp T. 1, Kotsar A. 1, Lang K. 2, Innos K. 3
1Tartu University Clinics; 2-University of Tartu, 1-Department of Urology and Kidney Transplantation; 2- Institute of Clinical Medicine, Tartu, Estonia; 3University of Tartu, Institute of Family Medicine and Public Health, Tartu, Estonia

35

DNA methylation profile of clear cell renal carcinoma
By: Kubiliute R. 1, Žalimas A. 2, Ulys A. 2, Jankevičius F. 2, Jarmalaitė S. 2
1Vilnius University, Life Sciences Center, Vilnius, Lithuania; 2National Cancer Institute, Scientific Research Center, Vilnius, Lithuania

36

Tumors of native kidneys in dialysed and in renal transplant patients
By: Čekas K., Ramonas H.
Centre of Urology, Vilnius University Hospital Santaros Klinikos, Vilnius University, Faculty of Medicine, Vilnius, Lithuania

37

Role of nephrometric scores in the prediction of warm ischemia time and the renal function outcomes in patients who underwent nephron-sparing surgery for renal cancer
By: Chaker K., Sellami A., Ouanes Y., Bibi M., Ben Chehida M.A., Abid K., Ben Rhouma S., Nouira Y.
La Rabta Hospital, Dept. of Urology, Tunis, Tunisia

38

Predictors of renal parenchymal volume loss after partial nephrectomy
By: Atalay H.A., Özbir S.
Okmeydani Teaching and Research Hospital, Dept. of Urology, Istanbul, Turkey

39

Surgery for metastases of renal cell carcinoma: Outcome of treatments and external assessment of Leuven-Udine prognostic groups
By: Erkkilä K., Visapää H., Kilpeläinen T., Taari K., Järvinen R., Tornberg S., Nisen H.
Retroperitoneal and transperitoneal laparoscopic cryoablation of small renal tumours - follow up study

By: Kailasa A.K., Rogers M., Khan I.
North Lincolnshire Acute and Goole Hospitals, Dept. of Urology, Scunthorpe, United Kingdom

Impact of the metabolic syndrome on the renal function after partial nephrectomy for non metastatic localized renal cell carcinoma

By: Chaker K., Ben Rhouma S., Sellami A., Ouanes Y., Bibi M., Ben Chehida M.A., Abid K., Nouira Y.
La Rabta Hospital, Dept. of Urology, Tunis, Tunisia

Renal function outcomes after partial nephrectomy and radical nephrectomy for small renal cancer: A comparative study

By: Chaker K., Sellami A., Ouanes Y., Bibi M., Ben Chehida M.A., Abid K., Ben Rhouma S., Nouira Y.
La Rabta Hospital, Dept. of Urology, Tunis, Tunisia

Overall survival in patients underwent open partial nephrectomy in a solitary kidney

By: Suslov L., Sukonko O., Polyakov S., Krasny S., Mirilenko L.
1N.N. Alexandrov National Cancer Centre, Dept. of Urology, Minsk, Belarus, 2N.N. Alexandrov National Cancer Centre, Cancer Control Department, Minsk, Belarus

Quality of life after medical versus surgical castration for locally advanced or metastatic prostate cancer

By: Chaker K., Sellami A., Ouanes Y., Ben Chehida M.A., Abid K., Ben Rhouma S., Nouira Y.
La Rabta Hospital, Dept. of Urology, Tunis, Tunisia

Long-term outcome of localized prostate cancer treated with brachytherapy

By: Vaiciunas K., Babakinis J., Jokubonis K., Jarusevicius L., Inciura A.
1The Hospital of Lithuanian University of Health Sciences Kauno klinikos, Dept. of Urology, Kaunas, Lithuania, 2The Hospital of Lithuanian University of Health Sciences Kauno klinikos, Dept. of Oncology and Hematology, Kaunas, Lithuania

4 years outcome in 143 patients receiving low-dose I125 brachytherapy

By: Purvaneckas J., Makevicius J., Rimas A., Sniureviciute M.
1Vilnius University, Faculty of Medicine, Dept. of Urology, Vilnius, Lithuania, 2Vilnius University, Center of Urology, Institute of Clinical Medicine Faculty of Medicine, Vilnius,
47 Influence of number of core with adenocarcinoma on Gleason score upgrade in patients undergoing radical prostatectomy

By: Ediz C.¹, Akan S.¹, Cakmak S.¹, Ates F.¹, Yilmaz Ö.¹, Temel M.C.¹, Koksal O.², Hayit H.¹, Sariogullari U.¹
¹SBU Sultan Abdulhamid Han Education and Research Hospital, Dept. of Urology, Istanbul, Turkey, ²SBU Sultan Abdulhamid Han Education and Research Hospital, Dept. of Biostatistics, Istanbul, Turkey

48 Effectiveness of salvage pelvic surgery for clinically recurrent prostate cancer after initial curative treatment: First experience of single tertiary center

By: Domarkas A., Auskalnis S., Jievaltas M., Milonas D.
Lithuanian University of Health Sciences, Dept. of Urology, Kaunas, Lithuania

49 Do the pelvic irradiation and adjuvant androgen-deprivation therapy improve efficacy of salvage radiotherapy in patients with biochemical recurrence after radical prostatectomy?

By: Polyakov S.¹, Semenov S.¹, Demeshko P.², Krasny S.¹
¹N.N. Alexandrov National Cancer Centre of Belarus, Dept. of Urology, Minsk, Belarus, ²N.N. Alexandrov National Cancer Centre of Belarus, Dept. of Radiology, Minsk, Belarus

50 Metastasis-free and cancer-specific survival after salvage radiotherapy in patients with biochemical recurrence treated with radical prostatectomy

By: Polyakov S.¹, Krasny S.¹, Demeshko P.², Semenov S.¹, Minich A.¹
¹N.N. Alexandrov National Cancer Centre of Belarus, Dept. of Urology, Minsk, Belarus, ²N.N. Alexandrov National Cancer Centre of Belarus, Dept. of Radiology, Minsk, Belarus

51 Blood-circulating androgen receptor variants as markers for progression and response to treatment in prostate cancer patients

By: Stuopelyte K.¹, Sestokaite A.¹, Haflidadottir B.S.², Visakorpi T.², Ulys A.³, Jankevicius F.³, Jarmalaite S.³
¹Vilnius University, Life Sciences Center, Vilnius, Lithuania, ²University of Tampere, Faculty of Medicine and Life Sciences, BioMediTech, Prostate Cancer Research Center, Tampere, Finland, ³National Cancer Institute, Vilnius, Lithuania

52 The importance of immediate prostate specific antigen value after radical prostatectomy on prediction of clinical progression in lymph node positive patients

By: Astrauskas M.¹, Cepas G.², Jievaltas M.¹, Milonas D.¹
¹Lithuanian University of Health Sciences, Dept. of Urology, Kaunas, Lithuania, ²Lithuanian University of Health Sciences, Medical Academy, Kaunas, Lithuania
Prognostic significance of time until biochemical recurrence on clinical progression in surgically treated high-risk prostate cancer patients

By: Venclovas Z., Auskalnis S., Jievaltas M., Milonas D.
Lithuanian University of Health Sciences, Dept. of Urology, Kaunas, Lithuania

68Ga-PSMA ligand PET/CT in patients with biochemical recurrence after prostate cancer treatment – initial data

By: Freimanis A., Lietuvietis V., Vjaters E., Roznere L., Zemniece L., Kalnina M., Tirane M., Radzina M.
1Riga East University Hospital, Clinic of Urology and Oncologic urology, Riga, Latvia,
2Pauls Stradins Clinical University Hospital, Clinic of Urology, Riga, Latvia,
3Riga Stradins University, Nuclear Medicine Clinic, Riga, Latvia,
4Riga Stradins University, Radiology Research Laboratory, Riga, Latvia

The effect of lymphadenectomy extent on early postoperative undetectable PSA rate among prostate cancer pT3b R0 patients at West-Tallinn Central Hospital

By: Okas R., Alas I.
1Tartu University, Faculty of Medicine, Tallinn, Estonia,
2West-Tallinn Central Hospital, Dept. of Urology, Tallinn, Estonia